July 1, 2020 -- Lantheus Medical Imaging will showcase the potential of its PyL (F-18 DCFPyL) radiopharmaceutical at the virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 annual meeting, July 11-14.
PyL is an investigational prostate-specific membrane antigen-targeted small-molecule PET radiopharmaceutical that aims to visualize prostate cancer. Data from company-sponsored studies of PyL will be presented on July 11 in the Science Pavilion at SNMMI 2020.
The information that will be presented evaluates the diagnostic performance and clinical impact of PyL in patients with biochemical recurrence of prostate cancer. Another abstract focuses on a digital solution Latheus is developing with PyL in the hopes of supporting prostate cancer staging with the use of the automated miPSMA index of the PET/CT PyL-prostate specific membrane antigen (PSMA) images.
Lantheus completes Progenics purchase
Lantheus Holdings, parent company of Lantheus Medical Imaging, has completed its purchase of oncology drug developer Progenics Pharmaceuticals.
Lantheus deal for Progenics gets shareholder nod
Lantheus Medical Imaging has received approval from its shareholders to move forward with its plan to acquire oncology drug developer Progenics Pharmaceuticals.
Pandemic will affect Lantheus 2020 financial results
Lantheus Medical Imaging parent Lantheus Holdings has announced the ongoing COVID-19 pandemic has impacted its financial predictions for 2020.
Lantheus reports revenue increases for Q4, 2019
Lantheus Medical Imaging parent Lantheus Holdings has reported growth in 2019 fourth-quarter and full-year revenues, although its net income declined.
Curium, Progenics partner on PET agent in Europe
Global nuclear medicine firm Curium has joined Progenics Pharmaceuticals in an exclusive agreement to develop and commercialize Progenics' prostate-specific...